Today: 9 June 2026
Magnum Ice Cream Buyout Buzz: Blackstone and CD&R Circle Ben & Jerry’s Owner After Stock Slide
15 May 2026
2 mins read

Magnum Ice Cream Buyout Buzz: Blackstone and CD&R Circle Ben & Jerry’s Owner After Stock Slide

LONDON, May 15, 2026, 14:07 BST

Blackstone and Clayton, Dubilier & Rice have started looking at possible bids for The Magnum Ice Cream Company N.V.—the company behind Ben & Jerry’s and Cornetto—according to two sources cited by Reuters on Friday. Magnum shares surged close to 16% following the news, heading for their steepest one-day climb since the stock’s debut.

Timing is crucial here. Magnum only separated from Unilever under six months back, hitting the market around a 7.8 billion euro valuation. The shares slipped from a peak of 16.5 euros earlier this year, now hovering just above their initial listing price.

The interest comes just ahead of the crucial summer stretch, when ice cream sales matter most to the company. According to Reuters, buyout groups have been tracking Magnum’s stock and eyeing summer sales numbers before making any call. None of the parties—Magnum, Unilever, Blackstone, or CD&R—commented.

Magnum, based in the Netherlands, trades in Amsterdam, London, and New York. After spinning off the business, Unilever kept a stake just under 20%—that’s set to be sold gradually to help cover separation expenses and keep capital options open.

Magnum’s U.S. filing, dated April 30, put its outstanding ordinary shares at 612.3 million as of April 29. The company’s ordinary shares are listed under the MICC ticker on Euronext Amsterdam, the London Stock Exchange, and the New York Stock Exchange.

There’s little sign of trouble in Magnum’s newest trading update. First-quarter revenue came in at 1.77 billion euros, down 1.2% on a reported basis, hit by foreign-exchange moves. Strip out currency effects, though, and organic sales climbed 4.5% — the company’s preferred gauge of underlying growth.

Chief Executive Peter Ter Kulve said the company is “well set up for the summer season” and stuck with its 2026 guidance, calling for organic sales growth of 3% to 5% and an improvement in the underlying margin. Magnum Ice Cream News

The bid boils down to brands, heft, and a chance to juice margins. As Reuters pointed out, private equity players are eyeing turnaround potential via trimming costs and pushing up profitability—particularly with Froneri in the mix, the PAI Partners and Nestle-backed venture pegged at 15 billion euros as of October’s deal.

Magnum claims a 21% slice of the $87 billion global ice cream market—well ahead of Froneri, which sits at 11%. That kind of lead hands a buyer a big base to build from. But it also leaves the company more vulnerable to shifts within the category than if it were part of a more diversified food group.

Risks are in plain sight. The rise of GLP-1 appetite-suppressing drugs has already shaken up segments like snacks and desserts, with no sign of that health trend slowing down. Jack Martin, investment director at Oberon Investments, pointed to “regulatory headwinds against unhealthy foods” and added, “GLP-1s are a potential headwind,” speaking to Reuters at Magnum’s debut. Reuters

Ben & Jerry’s brings its own set of challenges to the table. Earlier this month, a cohort of Magnum investors took aim at the company, raising issues about Ben & Jerry’s approach to social activism and its financial disclosures. Magnum pushed back—saying it “respectfully disagrees” with that assessment, and that it’s sticking with a board chaired by an independent director to safeguard the brand’s social mission and standards. Reuters

Magnum pointed to ongoing uncertainty in the Middle East and flagged potential impacts on input costs, though it said its direct exposure to the region is limited and mitigation efforts are in progress. For bidders sizing up the company, the focus shifts from brand recognition to the summer—whether sales deliver sufficient momentum on volume, pricing, and margins to support a take-private bid.

Stock Market Today

  • Toast (TOST) Stock Down 29% YTD Amid Mixed Valuation Signals
    June 9, 2026, 9:43 AM EDT. Toast (TOST) shares have fallen 29.2% year to date, hitting $24.10 after a 16.6% slide over three months. Market debate centers on whether the current price undervalues Toast's growth prospects or reflects headwinds in hospitality tech. A popular valuation narrative pegs fair value at $33.96, citing demand for Toast's AI-driven restaurant tools amid labor shortages and expansion into new markets. This represents a 29% discount to current trading levels. However, risks remain, including high sales costs and margin pressure from competition and tariffs. Investors weigh steady revenue growth and margin improvement against these challenges as Toast navigates a turbulent period.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
AmpliTech’s 5G Radio Test Moves AMPG Shares

AmpliTech’s 5G Radio Test Moves AMPG Shares

9 June 2026
AMPG soared 26.7% to $6.57 after AmpliTech revealed its 64T64R Massive MIMO radio was the only one of its kind at O-RAN PlugFest, showing interoperability with major carriers’ equipment, but no new orders were announced, leaving sales conversion as the key investor focus.
Why Cerebras Stock Is Down Today: Wall Street Hits the Brakes After a Blowout AI IPO
Previous Story

Why Cerebras Stock Is Down Today: Wall Street Hits the Brakes After a Blowout AI IPO

Why Is Bitcoin Down Today? BTC Slips Below $80,000 as Hot Inflation, Yields and ETF Wobbles Hit Crypto
Next Story

Why Is Bitcoin Down Today? BTC Slips Below $80,000 as Hot Inflation, Yields and ETF Wobbles Hit Crypto

Go toTop